ACTRN12613001154796尚未招募2 期
A phase 2 trial of cyclophosphamide as prophylaxis for graft-versus-host disease after HLA-identical allogeneic donor transplantation using reduced intensity conditioning therapy
Westmead Hospital0 个研究点目标入组 24 人开始时间: 2013年10月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 15 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1. Age 15-70 years
- •2.High risk hematological malignancy suitable for treatment with an allogeneic transplant (acute leukaemia in first remission with poor risk cytogenetics or unfavourable gene mutation profile, or in second or subsequent remission, chronic myeloid leukaemia in first chronic phase not responding to tyrosine kinase inhibitor therapy, poor risk myelodysplastic syndrome, Hodgkin or non-Hodgkin lymphoma failing conventional therapy).
- •3.Suitable HLA-matched related donor (6/6 match for A, B, DRB1) or unrelated volunteer donor (8 locus match for A, B, C, and DRB1 at allelic level) identified and available.
排除标准
- •1. Serious organ dysfunction or uncontrolled infection
- •2.HIV positive
- •3.Uncontrolled hepatitis B or C.
研究者
相似试验
进行中（未招募）
不适用
Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relpased or refractory multiple myeloma patients.Relasped and Refractory Mulitple MyelomaMedDRA version: 18.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2014-004511-36-GBniversity Of Leeds250
进行中（未招募）
1 期
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88
进行中（未招募）
不适用
An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - NDEUCTR2007-006037-13-ITOSPEDALE POLICLINICO S. MATTEO
进行中（未招募）
2 期
Short treatment with the drug cyclophosphamide in bowel cancerStage II-IVA diagnosed colorectal cancerBowel cancerCancerISRCTN12508004Cardiff University500
已完成
2 期
A parallel randomised phase II trial of cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) chemotherapy with or without Bortezomib in relapsed mantle cell lymphomaRelapsed or refractory mantle cell lymphomaMantle cell lymphomaCancerISRCTN20159589Plymouth Hospitals NHS Trust (UK)90